Equities analysts expect that Humana Inc. (NYSE:HUM) will report earnings per share (EPS) of $2.00 for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Humana’s earnings, with the lowest EPS estimate coming in at $1.95 and the highest estimate coming in at $2.06. Humana reported earnings per share of $2.09 during the same quarter last year, which would suggest a negative year-over-year growth rate of 4.3%. The company is scheduled to report its next quarterly earnings report on Wednesday, February 14th.
According to Zacks, analysts expect that Humana will report full year earnings of $11.63 per share for the current fiscal year, with EPS estimates ranging from $11.52 to $11.80. For the next year, analysts expect that the business will post earnings of $12.12 per share, with EPS estimates ranging from $11.95 to $12.36. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Humana.
Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, November 8th. The insurance provider reported $3.39 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.27 by $0.12. Humana had a net margin of 3.49% and a return on equity of 15.99%. The firm had revenue of $13.28 billion during the quarter, compared to analyst estimates of $13.41 billion. During the same quarter in the prior year, the firm earned $3.18 EPS. The business’s revenue for the quarter was down 3.0% compared to the same quarter last year.
Several equities research analysts have recently commented on HUM shares. Credit Suisse Group reduced their price target on shares of Humana from $256.00 to $246.00 and set a “neutral” rating for the company in a research report on Friday, November 10th. ValuEngine lowered shares of Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. BidaskClub raised shares of Humana from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd. Jefferies Group LLC reaffirmed a “hold” rating and set a $257.00 price target on shares of Humana in a research report on Friday, October 13th. Finally, BMO Capital Markets upped their price target on shares of Humana from $290.00 to $300.00 and gave the company an “outperform” rating in a research report on Friday, November 10th. Thirteen research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Humana currently has an average rating of “Hold” and an average target price of $252.81.
Shares of Humana (NYSE HUM) opened at $238.30 on Thursday. Humana has a 52-week low of $186.25 and a 52-week high of $264.56. The company has a market cap of $34,040.00, a PE ratio of 19.92, a PEG ratio of 1.61 and a beta of 0.90. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.61 and a current ratio of 1.61.
The company also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Friday, December 29th will be given a dividend of $0.40 per share. The ex-dividend date is Thursday, December 28th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.67%. Humana’s dividend payout ratio is currently 12.60%.
In other news, insider Elizabeth D. Bierbower sold 9,786 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $259.00, for a total transaction of $2,534,574.00. Following the completion of the transaction, the insider now directly owns 18,042 shares in the company, valued at approximately $4,672,878. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Timothy S. Huval sold 7,803 shares of the stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $258.14, for a total value of $2,014,266.42. Following the transaction, the vice president now owns 8,831 shares of the company’s stock, valued at $2,279,634.34. The disclosure for this sale can be found here. 0.80% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of HUM. WFG Advisors LP lifted its position in Humana by 4.5% in the second quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock worth $113,000 after buying an additional 20 shares during the last quarter. Fieldpoint Private Securities LLC bought a new stake in Humana in the third quarter worth $115,000. Acrospire Investment Management LLC bought a new stake in Humana in the second quarter worth $120,000. Northwestern Mutual Wealth Management Co. lifted its position in Humana by 139.5% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 558 shares of the insurance provider’s stock worth $134,000 after buying an additional 325 shares during the last quarter. Finally, Fiduciary Trust Co. bought a new stake in Humana in the second quarter worth $135,000. Institutional investors own 96.70% of the company’s stock.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.